莱西康制药 LXRX
$1.78 +$0.17 (+10.56%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $1.78 0.00%
开盘$1.66
昨收$1.61
当日区间$1.61 – $1.84
成交量3.60M
市值$792.52M
市盈率（TTM）–
股息率–
财报
财报日平均波动±8.1%近16次财报
收涨次数9 / 1656% 的概率
最佳反应+22.9%
最差反应-16.1%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±24.3% | -3.67% | 符合区间 |
| 2026/Q1 | 7 May 2026 | Pre Market | ±18.8% | +5.00% | 符合区间 |
| 2025/Q4 | 5 Mar 2026 | Pre Market | ±24.5% | +0.61% | 符合区间 |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±39.9% | +3.62% | 符合区间 |
| 2025/Q2 | 6 Aug 2025 | Pre Market | ±35.7% | +9.52% | 符合区间 |
| 2025/Q1 | 13 May 2025 | After Market | ±36.5% | -15.57% | 符合区间 |
| 2024/Q4 | 6 Mar 2025 | After Market | ±62.6% | +6.55% | 符合区间 |
| 2024/Q3 | 12 Nov 2024 | After Market | ±37.2% | -8.40% | 符合区间 |
| 2024/Q2 | 1 Aug 2024 | After Market | ±21.1% | -16.09% | 符合区间 |
| 2024/Q1 | 2 May 2024 | After Market | ±17.6% | +2.35% | 符合区间 |
| 2023/Q3 | 8 Nov 2023 | Pre Market | ±104.0% | -8.80% | 符合区间 |
| 2023/Q2 | 3 Aug 2023 | After Market | ±18.2% | -2.60% | 符合区间 |
| 2023/Q1 | 2 May 2023 | After Market | ±23.9% | +15.13% | 符合区间 |
| 2022/Q4 | 2 Mar 2023 | After Market | ±14.2% | +22.94% | 超出定价预期 |
| 2022/Q3 | 9 Nov 2022 | Pre Market | ±14.6% | -4.85% | 符合区间 |
| 2022/Q2 | 2 Aug 2022 | After Market | ±30.5% | +3.46% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$692,000.00-97.6% YoY
营业利润-$26.54M-810.4% YoY
净利润-$31.78M-1,077.1% YoY
摊薄每股收益-$0.07-800.0% YoY
自由现金流-$9.19M-154.1% YoY
经营现金流-$9.19M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率99.1%
营业利润率-131.4%
净利率-147.4%
净资产收益率-40.2%
资产收益率-25.7%
投入资本回报率-28.0%
流动比率13.37
负债/资产比率30.2%
现金及投资$190.61M
总负债$57.64M
净现金（净负债）$132.97M
暂无评论——快来第一个聊聊 LXRX。
登录后参与讨论。